Inspire Pharmaceuticals says it has reached deal
Published: Wed, Oct. 01, 2008 12:30AM
Modified Wed, Oct. 01, 2008 06:08AM
E-Mail
Print
tool name
closeDURHAM -- Inspire Pharmaceuticals said in a regulatory filing Tuesday that it has settled a Securities and Exchange Commission investigation related to the clinical trials of its experimental dry-eye treatment.
The SEC opened a formal probe of the Durham company in August 2005 because of possible omissions and misstatements in reports to investors. CEO Christy Shaffer and Mary Bennett, who served as executive vice president of operations and communications, also were implicated.
Inspire reported that neither the company nor Shaffer and Bennett admitted or denied findings of the probe and that the settlement did not include fines or other sanctions. The company did not provide further details.
More Business
All rights reserved. This copyrighted material may not be published, broadcast or redistributed in any manner.
Get it all with convenient home delivery of The News & Observer.
Staff writer John Murawski; Staff writer Alan M. Wolf; Staff writer Sue Stock; Staff writer Jonathan B. Cox
The News & Observer is pleased to be able to offer its users the opportunity to make comments and hold conversations online. However, the interactive nature of the internet makes it impracticable for our staff to monitor each and every posting.
Since The News & Observer does not control user submitted statements, we cannot promise that readers will not occasionally find offensive or inaccurate comments posted on our website. In addition, we remind anyone interested in making an online comment that responsibility for statements posted lies with the person submitting the comment, not The News and Observer.
If you find a comment offensive, clicking on the exclamation icon will flag the comment for review by the administrators, we are counting on the good judgment of all our readers to help us.
